Categories
Aurobindo Pharma Limited — Board Meeting, 21-05-2026: Outcome of Board Meeting
21-05-2026 · 07:40 pm
Aurobindo Pharma's board approved solid Q4FY26 consolidated PAT of ₹920.84 Cr on ₹8,853.34 Cr revenue. Full-year PAT reached ₹3,502.97 Cr, revenue ₹33,653.08 Cr. Also, a new secretarial auditor was appointed, and internal auditors re-appointed. $AUROPHARMA focuses on performance & governance.
No comments yet. Be the first to comment!